علاج اعتلال الشبكية السكري في الوذمة البقعية السكرية المركزية

References

• Diabetic macular edema should be classified as either center-involved (CI-DME) or non-center-involved DME (NCI-DME).
• Because the risk of visual loss is greatest if macular edema is at the center of the macula, DME is now subdivided as either CI-DME or NCI-DME.
• Multiple, high-quality clinical trials and systematic reviews have demonstrated that anti-VEGF therapy is more effective in improving vision in eyes with CI-DME than monotherapy with focal laser surgery treatment, thus supplanting focal laser surgery as the first-line therapy.
• Based on these studies, anti-VEGF therapy is the initial treatment choice for CI-DME, with possible subsequent focal laser surgery treatment for persistent edema.
• In eyes with good visual acuity and CI-DME, treatment is reasonably deferred until the visual acuity is affected (20/30 or worse).
• Individuals receiving the intravitreal injections of anti-VEGF agents may be examined at 1 month following therapy.